指南与共识儿科与产科急症呼吸衰竭与机械通气重症综合管理与镇静镇痛

儿童和青少年COVID-19预防与管理指南:儿童感染病学会儿童COVID-19治疗工作组共识声明

Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce.
指南 / 共识 · J Pediatric Infect Dis Soc · 2024-01-01
一句话结论儿童感染病学会工作组基于专家共识提出儿童和青少年COVID-19风险分层、治疗和预防建议,识别可指导临床决策的重症风险因素。

该共识由21家北美机构的儿童感染病、儿童感染病药理学和儿童重症医学专家组成的工作组制定,通过电话会议、网络调查和系统评价及荟萃分析形成风险分层、治疗和预防建议。共识指出存在可识别的临床特征用于重症COVID-19风险分层,这些风险因素可用于指导住院和非住院儿童及青少年的治疗,并在有预防选择时指导预防性治疗。

要点

  • 工作组由21家北美机构的儿童感染病、药理学和重症医学专家组成,通过专家共识制定风险分层、治疗和预防建议。
  • 存在可识别的临床特征,可用于对儿童和青少年进行重症COVID-19风险分层。
  • 风险因素可用于指导住院和非住院儿童及青少年的COVID-19治疗。
  • 风险因素也可在有预防选择时指导预防性治疗。

适用人群与场景

  • 儿童和青少年COVID-19患者,包括住院和非住院人群。

研究设计与关键结果

  • 制定机构为儿童感染病学会儿童COVID-19治疗工作组,来自21家地理分布多样的北美机构。
  • 方法为重新召集专家组,通过一系列电话会议和网络调查,以及针对风险因素数据的系统评价与荟萃分析,基于专家共识制定并完善了包含风险分层、治疗和预防系列建议的指导声明。

证据类型、等级与局限

  • 证据类型:专家共识,基于系统评价与荟萃分析及专家共识制定。
  • 局限:原文未报告局限性

对床旁实践的改变

  • 作者认为,可识别的临床特征可用于住院和非住院儿童及青少年的COVID-19风险分层,并指导治疗;在有预防选择时,风险因素也可指导预防性治疗。

指南或共识出处

  • 儿童感染病学会儿童COVID-19治疗工作组共识声明(Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce),发表于J Pediatric Infect Dis Soc。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Since November 2019, the SARS-CoV-2 pandemic has created challenges for preventing and managing COVID-19 in children and adolescents. Most research to develop new therapeutic interventions or to repurpose existing ones has been undertaken in adults, and although most cases of infection in pediatric populations are mild, there have been many cases of critical and fatal infection. Understanding the risk factors for severe illness and the evidence for safety, efficacy, and effectiveness of therapies for COVID-19 in children is necessary to optimize therapy.

METHODS: A panel of experts in pediatric infectious diseases, pediatric infectious diseases pharmacology, and pediatric intensive care medicine from 21 geographically diverse North American institutions was re-convened. Through a series of teleconferences and web-based surveys and a systematic review with meta-analysis of data for risk factors, a guidance statement comprising a series of recommendations for risk stratification, treatment, and prevention of COVID-19 was developed and refined based on expert consensus.

RESULTS: There are identifiable clinical characteristics that enable risk stratification for patients at risk for severe COVID-19. These risk factors can be used to guide the treatment of hospitalized and non-hospitalized children and adolescents with COVID-19 and to guide preventative therapy where options remain available.

来源:J Pediatric Infect Dis Soc,查看原文。版权归原作者所有。

参考来源

  1. Willis ZI, Oliveira CR, Abzug MJ, et al. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. J Pediatric Infect Dis Soc. 2024. PMID: 38339996. doi:10.1093/jpids/piad116

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。